Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0M8AI
|
|||
| Former ID |
DNCL002411
|
|||
| Drug Name |
ARRY-380
|
|||
| Synonyms |
937265-83-3; ARRY-380 Analog; ARRY-380 (analog ); UNII-H32S1659ED; HER2-Inhibitor-1; H32S1659ED; 6-[5-[[[2-(Methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-N-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]-4-quinazolinamine; HER2 Inhibitor 1; SCHEMBL10169911; C29H27N7O4S; DTXSID00239555; MolPort-023-293-540; HMS3656B04; BDBM185146; EX-A1261; AOB87708; BCP02833; ZINC73096245; 2227AH; s2752; AKOS026750520; CS-0484; SB16599; BCP9000319; NCGC00346672-01; NCGC00346672-06
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1 | [1] | |
| Company |
Array BioPharma
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C29H27N7O4S
|
|||
| Canonical SMILES |
CC1=C(C=CC(=C1)NC2=NC=NC3=C2C=C(C=C3)C4=CC=C(O4)CNCCS(=O)(=O)C)OC5=CC6=NC=NN6C=C5
|
|||
| InChI |
1S/C29H27N7O4S/c1-19-13-21(4-7-26(19)39-22-9-11-36-28(15-22)32-18-34-36)35-29-24-14-20(3-6-25(24)31-17-33-29)27-8-5-23(40-27)16-30-10-12-41(2,37)38/h3-9,11,13-15,17-18,30H,10,12,16H2,1-2H3,(H,31,33,35)
|
|||
| InChIKey |
QVMNYGOVNWWFKF-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 937265-83-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01921335) ARRY-380 + Trastuzuamab for Breast w/ Brain Mets. U.S. National Institutes of Health. | |||
| REF 2 | ARRY-380, a Potent, Small Molecule Inhibitor of ErbB2, Increases Survival in Intracranial ErbB2+ Xenograft Models in Mice | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.